6
In the United States, the application of gene therapy against Duchenne Muskeldystrophy was stopped after three deaths, as was known a few days ago. The gene therapy developed by the biotech company Sarepta and initially approved by the US drug authority FDA is therefore confronted with an enormous setback. The Europe reached the case on Thursday: The independent expert committee of the EU drug authority (CHMP) recommended that the form of treatment was not allowed at all, as was announced on Friday.
